Immuneering Reports Positive Initial Data For IMM-1-104 In Phase 2a Pancreatic Cancer Trial;stock Up
13/9 05:40
(RTTNews) - Immuneering Corp. (IMRX) announced positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first line pancreatic cancer as part of its ongoing Phase 2a clinical trial....